FDA Recalls Monitoring: Internal Efficiency Grows, But Website Lags
This article was originally published in The Silver Sheet
Executive Summary
DEVICE RECALLS FALL 10% IN 2003, returning to 2001 level, with 527 actions reported. FDA is using its new Recall Enterprise System to electronically track each recall, but has yet to launch the long-promised public arm of the system. Meanwhile, agency staff say a manufacturer’s overall state of control may be called into question by a recall. "When you call me about a recall, you’re telling me that the quality control system in your firm works or it doesn’t work," says a Detroit compliance officer. To avoid a warning letter after a recall, companies should investigate why the problem occurred and take action to prevent a recurrence, agency staff advise
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.